El interés en corto de Macrogenics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Macrogenics. Los datos de interés en corto se actualizan cada dos semanas.

Macrogenics (NASDAQ:MGNX) Bolsa, Informe de interés en corto

Macrogenics

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).

Macrogenics Inc

<p>HC Wainwright &amp; Co.  analyst Robert Burns   reiterates Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) with a Neutral and maintains $4 price target.</p>


News

Price Target

Reiteration

Analyst Ratings

MGNX

HC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $4 Price Target

<h3>Gainers</h3>
<ul>
<li><strong>Regenxbio</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) stock increased by 16.6% to $10.4 during Wednesday's pre-market session. The market value of their outstanding shares is at $514.0 million. As per the press release, Q3 earnings came out today. </li>
<li><strong>Tango Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) shares increased by 15.83% to $6.0. The market value of their outstanding shares is at $642.8 million. </li>
<li><strong>Macrogenics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) shares increased by 15.11% to $4.34. The company's market cap stands at $272.2 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li><strong>Xylo Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XYLO#NASDAQ">XYLO</a>) stock rose 14.4% to $3.97. The market value of their outstanding shares is at $7.5 million. </li>
<li><strong>Globus Medical</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) shares moved upwards by 13.77% to $85.99. The market value of their outstanding shares is at $11.6 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li><strong>Processa Pharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock increased by 13.63% to $1.25. The company's market cap stands at $4.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Exact Sciences</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) stock decreased by 26.6% to $52.5 during Wednesday's pre-market session. The company's market cap stands at $9.7 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li><strong>Bluejay Diagnostics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) shares declined by 24.53% to $0.1. The company's market cap stands at $1.7 million. </li>
<li><strong>Altamira Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTO#NASDAQ">CYTO</a>) stock declined by 21.16% to $0.41. The market value of their outstanding shares is at $1.5 million. </li>
<li><strong>PACS Group</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>) shares decreased by 20.49% to $23.49. The market value of their outstanding shares is at $3.6 billion. </li>
<li><strong>Evotec</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) stock fell 19.66% to $3.68. The company's market cap stands at $1.3 billion. As per the press release, Q3 earnings came out today. </li>
<li><strong>Bionomics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares declined by 15.93% to $0.41. The market value of their outstanding shares is at $5.4 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Movers

BJDX

BNOX

CYTO

EXAS

GMED

PACS

PCSA

RGNX

TNGX

XYLO

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

WIIM

MacroGenics shares are trading higher after the company reported better-than-expected Q3 financial results.

<p>Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) reported quarterly earnings of $0.90 per share which beat the analyst consensus estimate of $0.21 by 328.57 percent. This is a 221.43 percent increase over earnings of $0.28 per share from the same period last year.  The company reported quarterly sales of $110.71 million which beat the analyst consensus estimate of $76.11 million by 45.46 percent.  This is a 964.81 percent increase over sales of $10.40 million the same period last year.</p>


Earnings

Earnings Beats

Macrogenics Q3 EPS $0.90 Beats $0.21 Estimate, Sales $110.71M Beat $76.11M Estimate

<p>Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) is preparing to release its quarterly earnings on Tuesday, 2024-11-05. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Macrogenics to report an <strong>earnings per share</strong> (EPS) of $0.21.</p>
<p>The market awaits Macrogenics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company's EPS missed by $0.30 in the last quarter, leading to a 7.14% drop in the share price on the following day.</p>
<p>Here's a look at Macrogenics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.59</td>
<td>-0.64</td>
<td>-0.15</td>
<td>-0.10</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.89</td>
<td>-0.84</td>
<td>-0.75</td>
<td>0.28</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-7.000000000000001%</td>
<td>-77.0%</td>
<td>-15.0%</td>
<td>17.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730750564_0.png" alt="eps graph" /></p>
<h3>Tracking Macrogenics's Stock Performance</h3>
<p>Shares of Macrogenics were trading at $3.87 as of November 01. Over the last 52-week period, shares are down 41.99%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Views on Macrogenics</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Macrogenics.</p>
<p>Analysts have provided Macrogenics with 4 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $6.75, suggesting a potential 74.42% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of  and Precigen, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>The prevailing sentiment among analysts is an Buy trajectory for Precigen, with an average 1-year price target of $5.5, implying a potential 42.12% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>Within the peer analysis summary, vital metrics for  and Precigen are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Macrogenics</td>
<td>Neutral</td>
<td>-17.81%</td>
<td>$7.97M</td>
<td>-67.89%</td>
</tr>
<tr>
<td>Precigen</td>
<td>Buy</td>
<td>-59.42%</td>
<td>$-297K</td>
<td>-83.88%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Macrogenics is positioned at the top for Revenue Growth with a decline of 17.81%, while its peer is at the bottom with a decrease of 59.42%. In terms of Gross Profit, Macrogenics is ahead with $7.97M, compared to its peer with $-297K. For Return on Equity, Macrogenics is performing better with a decrease of 67.89% compared to its peer's 83.88%.</p>
<h3>Unveiling the Story Behind Macrogenics</h3>
<p>Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).</p>
<h3>A Deep Dive into Macrogenics's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Revenue Challenges:</strong> Macrogenics's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately <strong>-17.81%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Macrogenics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-515.55%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Macrogenics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-67.89%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Macrogenics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-24.77%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Macrogenics's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>0.59</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<p><a href="https://www.benzinga.com/quote/MGNX/earnings"><strong>To track all earnings releases for Macrogenics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Macrogenics Earnings Preview

Biotech

Health Care

Management

General

MacroGenics Says Scott Koenig Intends To Step Down As President And Chief Executive Officer Early Next Year. The Company's Board Of Directors Has Retained Heidrick & Struggles To Lead A Search Process To Identify Its Next CEO

<p>The transaction is expected to close in the&nbsp;fourth quarter&nbsp;of 2024, subject to customary closing conditions.</p>


Asset Sales

MacroGenics Enters Agreement With TerSera For Sale Of Global Rights Of MARGENZA; $40M To Be Paid At Closing And May Receive Additional Sales Milestone Payments Of Up To Of $35M

MacroGenics Enters Agreement With TerSera Therapeutics, Under Which TerSera Will Acquire Global Rights To MARGENZA; TerSera To Pay MacroGenics $40M At Closing And MacroGenics May Receive Milestones Up To $35M

<p>9 analysts have shared their evaluations of Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $6.78, a high estimate of $14.00, and a low estimate of $4.00. A 34.37% drop is evident in the current average compared to the previous average price target of $10.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726668050_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Macrogenics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$5.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$8.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Mayank Mamtani</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$5.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$9.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Macrogenics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Macrogenics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Macrogenics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Macrogenics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MGNX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Macrogenics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Macrogenics</h2>
<p>Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 × CTLA-4), Tebotelimab (PD-1 × LAG-3), MGD024 (CD123 × CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV × CD3).</p>
<h3>Unraveling the Financial Story of Macrogenics</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Macrogenics faced challenges, resulting in a decline of approximately <strong>-17.81%</strong> in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Macrogenics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-515.55%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Macrogenics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-67.89%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Macrogenics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-24.77%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.59</strong>, caution is advised due to increased financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Macrogenics Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)

<ul>
<li>Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORR</li>
<li>Patients remained on vobra duo through a median of 6 doses (ranging up to 12), representing an extension of treatment duration as compared to Phase 1 mCRPC dose expansion cohort</li>
<li>Company expects to have mature median rPFS no later than early 2025</li>
<li>MacroGenics to host an investor call to review key data presented at ESMO and provide a general corporate update on Monday, September 16, 2024, at 8:00 a.m. ET</li>
</ul>


Reported Sunday, MacroGenics Presents Efficacy And Safety Data For Vobra Duo In Phase 2 TAMARACK Study At ESMO 2024

MacroGenics shares are trading higher after the company announced it is set to present Phase 2 results from its TAMARACK trial on innovative cancer treatment at ESMO 2024.

<p>MacroGenics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced a poster presentation relating to Phase 2 data of vobramitamab duocarmazine in metastatic castration-resistant prostate cancer (mCRPC) at the European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain from September 13-17, 2024.</p>
<p>&nbsp;</p>


Reported Sunday, MacroGenics To Present Phase 2 Results From TAMARACK Trial On Innovative Cancer Treatment At ESMO 2024

<p>Across the recent three months, 8 analysts have shared their insights on Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $7.75, a high estimate of $14.00, and a low estimate of $4.00. A 43.1% drop is evident in the current average compared to the previous average price target of $13.62. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1723734065_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The perception of Macrogenics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$5.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$8.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Mayank Mamtani</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$5.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$9.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Kaveri Pohlman</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$9.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Macrogenics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Macrogenics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Macrogenics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Macrogenics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MGNX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Macrogenics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Macrogenics</h2>
<p>Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 × CTLA-4), Tebotelimab (PD-1 × LAG-3), MGD024 (CD123 × CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV × CD3).</p>
<h3>Breaking Down Macrogenics's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Macrogenics's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately <strong>-17.81%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Macrogenics's net margin excels beyond industry benchmarks, reaching <strong>-515.55%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Macrogenics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-67.89%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Macrogenics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-24.77%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.59</strong>, caution is advised due to increased financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Evaluating Macrogenics: Insights From 8 Financial Analysts

<p>Citigroup  analyst Yigal Nochomovitz   maintains Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) with a Buy and lowers the price target from $16 to $14.</p>


Citigroup Maintains Buy on Macrogenics, Lowers Price Target to $14

<p>BMO Capital  analyst Etzer Darout   maintains Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) with a Market Perform and lowers the price target from $8 to $5.</p>


BMO Capital Maintains Market Perform on Macrogenics, Lowers Price Target to $5

<p>Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) reported quarterly losses of $(0.89) per share which missed the analyst consensus estimate of $(0.59) by 50.85 percent. This is a 196.74 percent decrease over earnings of $0.92 per share from the same period last year.  The company reported quarterly sales of $10.80 million which missed the analyst consensus estimate of $21.24 million by 49.16 percent.  This is a 17.81 percent decrease over sales of $13.14 million the same period last year.</p>


Earnings Misses

Macrogenics Q2 EPS $(0.89) Misses $(0.59) Estimate, Sales $10.80M Miss $21.24M Estimate

<p>BTIG  analyst Kaveri Pohlman   downgrades Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) from Buy to Neutral.</p>


Downgrades

BTIG Downgrades Macrogenics to Neutral

Reports Q3 revenue $110.71M, consensus $76.11M. "The pending MARGENZA transaction as well as the recently received milestone payment from Incyte fu...

MacroGenics reports Q3 EPS 90c, consensus 21c

MacroGenics, Inc. (MGNX) Q2 2024 Earnings Call Transcript

TD Cowen analyst Tara Bancroft has maintained their neutral stance on MGNX stock, giving a Hold rating on October 23. Tara Bancroft's rating is bas...

MacroGenics: Navigating Efficacy and Safety Challenges in Vobra Duo Amidst Financial Stability

Warning: MGNX is at high risk of performing badly

MacroGenics Inc ( ($MGNX) ) has released its Q3 earnings. Here is a breakdown of the information MacroGenics Inc presented to its investors. MacroG...

MacroGenics Inc. Reports Strong Revenue Growth

Barclays analyst Peter Lawson maintained a Buy rating on MacroGenics (MGNX – Research Report) today and set a price target of $8.00. The company's ...

MacroGenics (MGNX) Gets a Buy from Barclays

Robert Burns, an analyst from H.C. Wainwright, reiterated the Hold rating on MacroGenics (MGNX – Research Report). The associated price target rema...

Balanced Hold Rating Reflects Cautious Optimism and Strategic Risks for MacroGenics

Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on MGNX stock, giving a Buy rating today. Jonathan Chang has given his ...

MacroGenics' Strategic Moves and Promising Pipeline Justify Buy Rating

Leerink keeps an Outperform rating on MacroGenics (MGNX) with an $8 price target following the Q3 report. The company recently announced it had sol...

MacroGenics Margenza rights sale a positive, says Leerink

B.Riley Financial analyst Mayank Mamtani has maintained their neutral stance on MGNX stock, giving a Hold rating today. Mayank Mamtani's rating is ...

MacroGenics' Transition Phase: Balancing Potential and Uncertainty Amid Leadership and Pipeline Developments

Legal

Press Releases

Shareholders of MacroGenics, Inc. Should Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights – MGNX

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc. - MGNX

Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc. - MGNX

MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®

Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and Maplebear - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call

MacroGenics Announces Leadership Transition

MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results

APLS

CART

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Macrogenics

Interés en corto

Macrogenics (NASDAQ:MGNX) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL